Obermatt
See Similar Stocks →

Anika Therapeutics

NSQ:ANIK · US0352551081
BiotechnologySmall

360

63
Profit price100
Owner Earnings Yield1
Dividend Yield1
Price/Sales86
EV / Gross Profit54
Price/Book70
Return on Capital85
Cash Return on Capital97
Return on Equity88
EBIT Margin67
Gross Profitability85
Accruals49
Owner Earnings Margin92
Sales growth42
Profit growth43
Reinvestment28
Price momentum46
Debt load36
Refinancing100
Debt Payback1
Liquidity49
Analyst ratings29
Opinion Changes50
Price Target Upside1
Market mood19
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Anika Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded1992
Employees261
Websiteanika.com
ISINUS0352551081
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Stem Cell TherapyOrthopaedicsPain ManagementSurgeryBiomedical EngineeringBiotechnologyHealth CareManufacturingScience and Engineering

Description

Anika Therapeutics, Inc. (Anika) operates as a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. The company develops minimally invasive products that restore active living for…

Analysis

Quality compounder

Anika Therapeutics, Inc. is a quality compounder: a well-run business trading at a price that reflects what it is worth.

Valuation data is not available for this company.

The trajectory is solid and the balance sheet is stretched. The company scores 2/20 on our value-creation score: not creating value.

What to watch: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
69
2026

All-time high

69

Jun 2026

All-time low

11

Mar 2026

Average rank

40

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
86
—
—
—
Price/Earnings
—
—
—
—
Price/Book
70
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
72
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Anika Therapeutics with its peers
Evolus
NMQ:EOLS
40
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
MacroGenics
NSQ:MGNX
24
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Pacific Biosciences of California
NSQ:PACB
16
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Atea Pharmaceuticals
NSQ:AVIR
5
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Esperion Therapeutics
NMQ:ESPR
9
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Aura Biosciences
NMQ:AURA
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →